Top Page
HeraMED Ltd.
(Sydney:HMD)
HeraMED Ltd. (HMD) vs. iShares MSCI Australia ETF (EWA)
HeraMED Ltd. Business Overview & Revenue Model
HeraMED Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 205.34K | 225.49K | 413.19K | 215.81K | 83.68K | 39.52K |
| Gross Profit | 119.83K | 135.29K | 248.12K | -214.69K | -219.50K | -279.32K |
| EBITDA | -2.48M | -3.35M | -3.97M | -3.17M | -3.93M | -3.45M |
| Net Income | -2.89M | -3.40M | -4.50M | -4.88M | -5.71M | -3.36M |
Balance Sheet | ||||||
| Total Assets | 1.04M | 2.78M | 2.01M | 4.19M | 4.57M | 3.17M |
| Cash, Cash Equivalents and Short-Term Investments | 628.17K | 3.13M | 723.29K | 2.64M | 3.55M | 1.94M |
| Total Debt | 0.00 | 815.96K | 209.37K | 179.53K | 3.41M | 190.47K |
| Total Liabilities | 658.25K | 1.06M | 1.55M | 1.30M | 4.13M | 1.19M |
| Stockholders Equity | 379.13K | 1.72M | 466.70K | 2.88M | -105.66K | 1.99M |
Cash Flow | ||||||
| Free Cash Flow | -2.55M | -2.98M | -5.57M | -3.20M | -3.20M | ― |
| Operating Cash Flow | -2.58M | -2.98M | -5.57M | -2.52M | ― | ― |
| Investing Cash Flow | 36.37K | 0.00 | -2.05K | -690.78K | -85.43K | -67.31K |
| Financing Cash Flow | 2.19M | 6.88M | 2.96M | 2.54M | 4.88M | 2.52M |
HeraMED Ltd. Technical Analysis
HeraMED Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$24.72M | -2.58 | -103.74% | ― | 14.84% | 39.64% | |
48 Neutral | AU$29.98M | -4.81 | -58.27% | ― | -7.20% | 28.70% | |
43 Neutral | AU$42.81M | -7.69 | -513.22% | ― | -34.06% | 75.47% | |
43 Neutral | AU$5.91M | -3.87 | ― | ― | ― | -55.00% | |
39 Underperform | AU$3.12M | -0.91 | -218.52% | ― | -30.80% | -38.95% | |
37 Underperform | AU$24.52M | -0.64 | -1476.79% | ― | -2.82% | 32.47% |
HeraMED Ltd. Corporate Events
HeraMED Ltd has applied to the ASX for quotation of 27,150,000 new ordinary fully paid shares under its ticker HMD, following the exercise or conversion of existing options or other convertible securities. The enlarged pool of quoted securities increases the company’s tradable equity base, potentially affecting liquidity and ownership structure, and marks a notable capital-related move for stakeholders to monitor in terms of future financing flexibility and market valuation.
HeraMED Limited announced an upcoming investor update webinar to discuss recent partnerships with Royal Philips and a pilot launch with Lee Health. The webinar will feature discussions on the company’s recent activities and future outlook, providing stakeholders an opportunity to engage with the leadership team.
HeraMED Ltd. announced the issuance of 1,000,000 fully paid ordinary securities to be quoted on the ASX, reflecting the company’s strategic move to enhance its capital structure. This development is expected to strengthen HeraMED’s market position and provide additional resources for its operational and growth initiatives.
HeraMED Limited has entered into a pilot agreement with Lee Health, a major US healthcare provider, to deploy its HeraCARE digital maternity solution. The pilot, valued at USD $115,000, will run for three to six months and aims to validate HeraCARE’s capabilities in enhancing patient engagement and remote pregnancy monitoring. If successful, the partnership could lead to a full-scale deployment, potentially managing 2,000 pregnancies annually. This collaboration marks a significant milestone for HeraMED in the U.S. market, positioning the company for scalable expansion and aligning its commercial model with Lee Health.
HeraMED Limited has announced a new commercial agreement with Telcare Medical Supply LLC, a subsidiary of Royal Philips, to deliver a comprehensive digital maternity care solution in the U.S. This collaboration combines Philips’ monitoring devices and infrastructure with HeraMED’s HeraCARE platform, providing a scalable remote patient monitoring ecosystem for U.S. hospitals and health systems. The initiative aims to enhance maternity care by integrating device data, clinical dashboards, and educational content, thereby supporting mothers and clinicians throughout the maternity journey. The agreement marks a significant step for HeraMED in expanding its market presence and offering innovative solutions to improve maternity care.
HeraMED Ltd. has requested a trading halt on its shares on the Australian Securities Exchange, effective immediately, pending an announcement regarding a strategic partnership agreement. This move is intended to help manage the company’s disclosure obligations and maintain an orderly market for its shares, with the halt expected to last until either the announcement is made or normal trading resumes on 25 November 2025.
HeraMED Limited has announced that its HeraBEAT fetal heart rate monitor has received an upgraded Class IIb regulatory classification from the TGA, making it the only remote home-use device of its kind approved for the Australian market. This new classification positions HeraBEAT uniquely in the market, opening significant commercial opportunities for HeraMED as it plans to expand its presence in Australia by targeting large health systems and private clinics.
HeraMED Limited, a leader in digital maternity care transformation, has announced a change in its registered office and principal place of business to a new location in Hawthorn East, VIC. This move is part of the company’s ongoing efforts to enhance its operations and maintain its position as a pioneer in the medical data and technology industry, particularly in the maternity care sector.
HeraMED Limited has reported significant progress in its third-quarter activities for fiscal year 2025, including a successful $1.98 million capital raise and advancements in U.S. commercial agreements. The company is finalizing two pivotal agreements with a global health-technology leader and a major U.S. health system, which are expected to enhance its market positioning and scalability in the U.S. market. Additionally, HeraMED has launched an AI and product strategy, including the AI Clinician Assistant and predictive-modeling initiatives, aimed at strengthening its innovation pipeline and creating new commercial pathways. The company is also advancing its research project with RMIT and Digital Health CRC, focusing on AI-driven predictive maternity care for culturally and linguistically diverse populations.
HeraMED Ltd. announced the issuance of 1,000,000 fully paid ordinary shares on the Australian Securities Exchange (ASX) under the code HMD. This move is part of the company’s strategy to enhance its market presence and provide additional value to its stakeholders by increasing liquidity and potentially funding future growth initiatives.
HeraMED Ltd. has announced the appointment of Sharon Howell as a director, effective from October 17, 2025. As part of her initial interest notice, Howell holds 2,200,003 fully paid ordinary shares and 2,000,000 unlisted options with an exercise price of $0.03, expiring on February 20, 2029. This appointment and the associated securities holdings reflect the company’s ongoing governance and strategic planning efforts, potentially impacting its market positioning and stakeholder interests.
HeraMED Limited has appointed Dr. Sharon R. Howell as a Non-Executive Director and Chair of the Advisory Board. Dr. Howell brings over two decades of global experience in healthcare and technology, having previously served as Chief Performance Officer at Centene Corporation. Her appointment is expected to bolster HeraMED’s strategic planning, healthcare technology partnerships, and commercialization efforts in the US and internationally. This move underscores the company’s commitment to scaling its impact in maternal health and expanding its international footprint.